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Abstract As heritability is high in attention-deficit/
hyperactivity disorder (ADHD), genetic factors must play
a significant role in the development and course of this
disorder. In recent years a large number of studies on
different candidate genes for ADHD have been published,
most have focused on genes involved in the dopaminergic
neurotransmission system, such as DRD4, DRD5, DAT1/
SLC6A3, DBH, DDC. Genes associated with the norad-
renergic (such as NET1/SLC6A2, ADRA2A, ADRA2C)
and serotonergic systems (such as 5-HTT/SLC6A4,
HTR1B, HTR2A, TPH2) have also received considerable
interest. Additional candidate genes related to neuro-
transmission and neuronal plasticity that have been
studied less intensively include SNAP25, CHRNA4,
NMDA, BDNF, NGF, NTF3, NTF4/5, GDNF. This
review article provides an overview of these candidate
gene studies, and summarizes findings from recently
published genome-wide association studies (GWAS).
GWAS is a relatively new tool that enables the identifi-
cation of new ADHD genes in a hypothesis-free manner.
Although these latter studies could be improved and need
to be replicated they are starting to implicate processes
like neuronal migration and cell adhesion and cell divi-
sion as potentially important in the aetiology of ADHD
and have suggested several new directions for future
ADHD genetics studies.
Keywords Genetics  ADHD  Candidate gene studies 
GWAS  Aetiology
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common, clinically heterogeneous (in terms of co-
morbidities, gender effects, courses and outcomes),
etiologically complex disorder characterized by early
onset of age-inappropriate persistent and pervasive
symptoms of inattention, hyperactivity, and impulsivity;
twin and adoption studies show ADHD to be highly
heritable, i.e., a heritability of around 0.76 [53]. Con-
verging evidence from animal and human studies
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implicates the dysregulation of frontostriatal and
frontocerebellar catecholaminergic circuits in the path-
ophysiology of ADHD [18]. In addition to prefrontal
cortical areas, the basal ganglia, cerebellum, temporal
and parietal cortex have been implicated in this con-
dition [27, 141]. ADHD is associated with various
neuropsychological alterations, such as deficits in vigi-
lance-attention, cognitive control, namely executive
function deficits, non-executive memory deficits, and
motivation, namely delay aversion, as well as milli-
second timing deficits, state regulation failures, intra-
individual fluctuations in performance over time, and an
altered sensitivity to stimulation [142, 163].
Up to now more than 1,800 publications, dealing with
the genetics of ADHD, have been published and the
following review will be representative and comprehen-
sive, but not exhaustive, and is meant to give the reader
an overview of current findings from genetic associa-
tion studies of this disorder including both candidate gene
studies and genome-wide association studies (GWAS).
Studies on gene-environment interaction in ADHD are
not included in this overview, but are reviewed in another
article in this edition [186]. For the detection of small
effects of individual genes, such as those likely to occur
in ADHD, genetic association studies [144] are generally
more suitable than genetic linkage analyses. However,
population stratification differences between case and
control samples can give rise to both type I and II errors
if case and control samples are not well matched for
ethnic background. Linkage studies have been extremely
successful in elucidating the causes of monogenic disor-
ders, but much less so in multifactorial disorders. ADHD
linkage studies have identified a number of genetic loci
(potentially) harbouring genes for ADHD and some
chromosome regions such as 5p13, 14q12, and 17p11
have been indicated in multiple studies [3, 7, 9, 50, 54,
73, 96, 131, 146]. In the most recent meta-analysis of
seven ADHD linkage studies, genome-wide significant
linkage was only confirmed for one locus on chromosome
16 [196].
Until recently, association approaches were restricted to
hypothesis-driven studies on candidate genes, as described
in the following paragraphs. Such approaches are sub-
stantially influenced by the amount of existing knowledge
regarding disease aetiology. Since this knowledge is still
limited for ADHD, candidate gene based studies are likely
to miss at least part of the genetic variance. Up to now,
such studies can explain no more than 3–5% of the total
genetic components of ADHD [98]. At the end of 2008, the
first unbiased, hypothesis-free GWAS were published for
ADHD, these will be reviewed below, after the candidate
gene studies.
Candidate gene approaches
Genes belonging to the dopaminergic neurotransmission
system—in particular the D4 dopamine receptor gene
(DRD4) and the human dopamine transporter gene (DAT1/
SLC6A3)—have been the most frequently investigated
genes. In addition, genes of the noradrenergic and the
serotonergic system have also been frequently studied. To
date, individual gene variants have only shown small
effects, rarely reaching an odds ratio of 1.3 (e.g. [53], a
figure consistent with that obtained from meta-analyses of
other complex traits [78].
Dopaminergic system
The effectiveness of methylphenidate, which acts by
blocking the dopamine transporter, in ADHD treatment as
well as the association of ADHD with those executive
neuropsychological functions and frontostriatal pathways,
that are dependent on an intact dopaminergic neurotrans-
mission make the dopaminergic system the most inten-
sively analyzed neurotransmitter system in ADHD [166].
D4 dopamine receptor gene (DRD4)
The association between ADHD and a 48 base-pair (48 bp)
repeat polymorphism of exon III of the DRD4 gene—
encoding a receptor expressed primarily in the prefrontal
cortex—is the strongest and most consistently replicated
molecular genetic finding in ADHD. A meta-analysis of
more than 30 studies found that the DRD4 7-repeat
(DRD4-7r) allele increases the risk for ADHD, although
this increase is only moderate with a pooled odds ratio of
1.34 [51, 98]. Importantly this finding was supported in
Caucasian as well as several non-Caucasian populations
[10, 17, 29, 66, 194]. In functional terms the DRD4 7-
repeat allele seems to alter the function of the encoded
receptor by making it less sensitive to dopamine than the
alternative alleles [5].
Studies of the cognitive correlates of the DRD4 7-repeat
allele in ADHD have found mixed results. A hypothesis
that the DRD4 7-repeat allele is particularly associated with
inattentiveness rather than hyperactivity or impulsivity, has
not yet been consistently confirmed [88, 120, 180].
Swanson et al. [165] were the first to report that carrier of
at least one 7-repeat allele with ADHD did not display
neuropsychological deficits. Moreover, the subgroup of
probands with ADHD but without a 7-repeat allele (non-
carriers) showed longer reaction times. Therefore, the 7-
repeat allele might be associated with behavioural features
rather than cognitive deficits. These findings were con-
firmed by the results of Manor and colleagues [117] and
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Bellgrove and colleagues [16], who showed that children
with ADHD with the 7-repeat allele exhibit better com-
mission and omission scores and lower reaction time var-
iability. Johnson et al. [79] support this hypothesis with a
spectral analysis of reaction time variability revealing that
absence of the 7-repeat allele is associated with drifting
sustained attention resulting in inconsistent performance
within a larger sample of Irish children with ADHD.
Contrary to these findings, Langley and colleagues [93]
report that carriers of the 7-repeat allele showed greater
impulsiveness (faster reaction time) than non-carriers;
Waldman et al. [179] referred to longer reaction times for
homozygous carriers of the 7-repeat allele and Kieling
et al. [82] described that presence of the 7-repeat allele was
associated with more commission errors during a contin-
uous performance task (CPT). Finally, Barkley and col-
leagues [12] reported no differences across a range of tests.
However, in summary association of high reaction time
variability with the 7-repeat allele absence appears to be
the most consistent result and seems to be specific to
ADHD [81]. The overall importance of these studies
seeking to link genotype with neuropsychological func-
tioning are limited by a range of methodological issues the
most important of which are, relatively small sample sizes,
a failure to account for the neuropsychological heteroge-
neity of ADHD, a lack of standardisation of neuropsy-
chological tasks between studies and the use of clinically
focused tasks rather than tasks that are based in neurosci-
ence [33]. For a more detailed review of the relationship
between candidate genes for ADHD and neuropsycholog-
ical phenotypes see [81].
Regarding correlates between specific DRD4 genotypes
and structural anatomical findings, Durston et al. [44]
suggested that variations in DRD4 influence prefrontal grey
matter volume in a sample of subjects that included indi-
viduals with ADHD as well as their unaffected siblings,
and healthy controls. Monuteaux et al. [125] also reported
findings in adults with ADHD showing that 7-repeat allele
carriers have a significantly smaller mean volume in the
superior frontal cortex and cerebellum cortex when com-
pared to subjects without this particular allele. Whilst Shaw
et al. [156] found that carrying the DRD4 7-repeat allele
was associated with having a thinner right orbitofrontal/
inferior prefrontal and posterior parietal cortex—regions
overlapping those found to be thinner in ADHD—this same
group were found to have better clinical outcomes. They
also had a distinct trajectory of cortical development with a
normalization of right parietal cortical thickening during
adolescence. This has also previously been linked to having
a better clinical outcome. However, two other studies
reported that possession of the DRD4 7-repeat allele was
associated with greater persistence of ADHD over time
[92]. Based on the finding that 7-repeat allele carriers more
likely exhibit antisocial behaviour, an alternative hypoth-
esis has been proposed which suggests that possession of
the DRD4 7-repeat allele influences the association
between ADHD and conduct disorder [76].
The most frequently investigated gene 9 gene or mar-
ker 9 marker interaction in ADHD is the interaction of
DRD4 (7-repeat allele) and DAT1 (10-repeat allele; see
below). Based on results of two studies on Chilean families,
Carrasco et al. [26] and Henriquez et al. [74] suggested that
neither the DRD4 7-repeat nor the DAT1 10-repeat allele
result in genotype frequency differences between affected
children and their healthy siblings. However, the simulta-
neous presence of both, DRD4 7-repeat heterozygosity and
DAT1 10-repeat allele homozygosity was more frequent in
affected children as compared to their healthy siblings. Qian
et al. [135] failed to replicate these initial findings. A fourth
study which tried to confirm the interaction in a Mexican
sample revealed no association with ADHD, neither for the
individual markers nor for their combination [59]. Kebir
et al. [81] analysed these markers and their relationship to
IQ in a French sample. Besides their not detecting an
association, they suggest that the verbal quotient as a spe-
cific domain of the IQ is correlated to the level of exter-
nalizing behaviour in boys with ADHD who carry the risk
genotypes of both markers. In fact Mill et al. [122] were the
first to suggest that DRD4 (and DAT1) exert their effects on
ADHD by influencing IQ in a population-based sample,
although it should be noted that Sonuga-Barke et al. [161]
were unable to replicate these findings in the sample of
the International Multi-centre ADHD Gene (IMAGE) pro-
ject. In sum, the publications on gene 9 gene interactions
are inconclusive and require further investigations in
much larger samples or a meta-analysis to rule out false
conclusions.
Other dopamine receptors
The 148 bp allele of a dinucleotide (CA)n repeat poly-
morphism located 18.5 kb 50 of the dopamine D5 receptor
gene (DRD5), has also received considerable attention.
While two meta-analyses supported an association with
ADHD (pooled odds ratio*1.3) [98, 112], Mill et al. [123]
and Loo et al. [110] found no evidence for a relationship
between DRD5 status and a range of cognitive endophe-
notypes of ADHD in samples of moderate size (for a more
detailed discussion of the endophenotype approach see
below). Recently, Langley et al. [92] reported an associa-
tion of the 148 bp allele with persistence of ADHD from
childhood to adolescence in a longitudinal study.
Allelic variants of the dopamine D1, D2 and D3
receptors have also been investigated with conflicting
results. A first study reported evidence for an association
between variants of DRD1 and ADHD. The receptor
Eur Child Adolesc Psychiatry (2010) 19:237–257 239
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encoded by this gene is mainly located in the prefrontal
cortex and in the striatum and it was suggested that it may
modulate working memory capacity and may be associated
specifically with inattention. The re-analysis of genotype
data of a GWAS of the IMAGE sample revealed nominal
significance of single nucleotide polymorphisms (SNPs) in
DRD1 for association to ADHD [130] as well as an asso-
ciation to time-to-onset of ADHD [94]. Two polymor-
phisms in the non-translated 50 region and one marker in
the non-translated 30 region were associated with an
increased risk for ADHD (odds ratio *1.3, each) [124].
This particular finding, however, was not replicated in a
candidate study in the IMAGE sample [21]. An association
of DRD2 SNPs with CPT phenotypes in ADHD has been
brought up by Kollins et al. [87]. Moreover, there is also
some evidence for an involvement of the dopamine D3
receptor gene (DRD3) in the aetiology of ADHD: Guan
et al. [65] reported a nominally significant association in a
Chinese Han population, whereas the results of Davis et al.
[37] indicate a role of the DRD3 in the manifestation of
hyperactive/impulsive symptoms of ADHD. However, the
findings concerning both DRD2 [87, 120, 180] and DRD3
[21, 37, 120, 180] are inconsistent and require further
investigation in independent samples.
Dopamine transporter gene (DAT1/SLC6A3)
The dopamine transporter is expressed primarily in the
striatum and the nucleus accumbens and is a site of action
of methylphenidate. Consequently, the association between
ADHD and variations in the DAT1 gene has been exten-
sively studied. The DAT1 gene contains a 40 bp variable
number tandem repeat (VNTR) polymorphism in the non-
translated 30 region. The 9-repeat allele (440 bp) (23.4%)
and the 10-repeat allele (480 bp) (71.9%) are the most
frequent alleles [177] in Caucasian populations. The 10-
repeat allele is possibly related to an increased mesolimbic
expression of the transporter [177].
Although there have been many reports supporting a
positive association between DAT1 and ADHD, there are
also negative findings. A recent meta-analysis found a
significant heterogeneity between family-based European
association studies (stronger effects) and Asian case–con-
trol studies (weaker effects), and did not support an overall
significant association between DAT1 and ADHD [98].
Further evidence of possible ethnicity effects comes from
studies that indicated associations in case–control studies
in Afro-Caribbean subjects [10] which were not detected in
Middle-Eastern subjects [10]. Similarly, a small Indian
family study found evidence for association of ADHD and
the shorter 9-repeat allele rather than the 10-repeat allele
usually found to be associated with ADHD in other studies
[36]. Another group has suggested that the 10-repeat allele
of DAT1 is associated with increased risk for ADHD only
in the presence of another functional variant. In two studies
they found increased risk only if a combination of the 10-
repeat allele and a 6-repeat allele of a 30-bp VNTR in
intron 8 of the DAT1 gene were both present [6, 23].
Whereas Bru¨ggemann and co-workers [25] did not find an
association for this haplotype with the adult form of
ADHD, Franke et al. [55] reported that the 9–6 haplotype
rather than the 10–6 haplotype is more likely to be asso-
ciated with childhood ADHD. This finding was recently
replicated in a sample of 1,440 ADHD cases which per-
sisted into adulthood and 1,769 controls from the Interna-
tional Multicentre persistent ADHD CollaboraTion
(IMpACT) project [57]. In a Brazilian sample, Genro et al.
[61, 62] found preferential transmission of a common
haplotype in the 50 region to offspring with ADHD whereas
they found no association to any haplotype in the 30 region
of the gene. Recently, further evidence for the presence of
at least two loci associated with ADHD within the DAT1
was described. While Friedel et al. [58] detected a haplo-
type spanning the first three introns of the gene with rela-
tive risks of 1.95 and 2.43 for heterozygous and
homozygous carriers, respectively, Brookes et al. [24]
replicated their initial association of SNPs at the 50 end of
the gene and identified a haplotype spanning the 50 and 30
markers. Underlining these observations, Xu et al. [193]
report an association of genetic variation in the promoter
region of DAT1 with ADHD in samples from both the UK
and Taiwan. Zhou et al. [195] suggested that the presence
or absence of conduct disorder might influence the asso-
ciation of DAT1 with ADHD. They analysed genotypes of
20 DAT1 markers in 576 trios, 141 of whom had comorbid
conduct disorder and found that DAT1 was only associated
with ADHD when conduct disorder was not present;
interestingly two independent association signals were
present in ADHD without CD (but not ADHD ? CD) at
both, the 50 and 30 end of the DAT1 gene. In addition, three
studies suggested that the genetic associations to ADHD
and in particular those for DAT1 may depend on gender:
While the effect sizes for the ADHD association observed
by Biederman et al. [19] were stronger when stratified by
sex, e.g. for DAT1 in males, Hawi et al. [72] reported
paternal over-transmission of risk alleles for ADHD,
especially for the VNTR in the 30 non-translated region. A
second study of the same group in 1,248 ADHD nuclear
families also provided support for a parent of origin effect
for the intron 8 and 30 non-translated region VNTRs as well
as the paternal risk haplotype of both [71]. Exploring
parent of origin effects in the IMAGE sample, Anney et al.
[2] found no evidence to support an overall parent of origin
effect for 554 independent markers of 47 ADHD candidate
genes, including markers in DAT1. Based on these con-
tradictory findings further studies of the association of the
240 Eur Child Adolesc Psychiatry (2010) 19:237–257
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DAT1 alleles and ADHD in large datasets that allow
investigating the role of age-related changes, ethnicity and
gender effects, gene-environmental interactions, parent of
origin effects, and the influence of comorbidity patterns are
needed.
Regarding structural anatomical correlates, Durston
et al. [44] reported that DAT1 variability influences cau-
date, but not prefrontal cortex volume. A functional
imaging study suggested that the DAT1 genotype affects
activation in the striatum and cerebellar vermis and that the
familial risk of ADHD is related to the striatum but not to
the vermis which requires further support [45].
There is also evidence that variations in the DAT1 gene
have a significant effect on aspects of executive neuro-
psychological functioning [80]. Significant genotype
effects were found for performance on the ‘‘Tower of
London’’ and on the ‘‘Wechsler Intelligence Scale for
Children Freedom From Distractibility Index’’; children
with ADHD with the 9-repeat/10-repeat genotype exhibited
poorer performance on these measures as compared to
children with the 10-repeat/10-repeat genotype [80]. Con-
trary to these findings, Bellgrove et al. [14] found that
ADHD patients with the 10-repeat/10-repeat genotype had
a greater attentional bias in a CPT than those with the other
allele combinations. Barkley et al. [12] again found effects
of DAT1 status on neuropsychological functioning, but
only in their control group where those with the 9-repeat/
10-repeat genotype performed less well on a CPT. Also,
Loo et al. [110] detected no relationship between DAT1
status and a range of cognitive performance measures in
children with ADHD. A systematic review of studies
investigating links between the VNTR in the 30 untrans-
lated region of the DAT1 and neurophysiological and
neuropsychological measures concluded that the majority
of studies did not find a relation between DAT1 and either
of these measures [148]. An associated study of 350 chil-
dren and adolescents with ADHD and 195 non-affected
siblings using a broad set of executive/cognitive and motor
tests concluded that whilst several of the DAT1 polymor-
phisms were associated with ADHD and whilst ADHD was
associated with impaired neuropsychological functioning,
none of the DAT1 polymorphisms was convincingly asso-
ciated with neuropsychological dysfunctions [148]. As
before the relevance of the studies investigating potential
links between genotype and neuropsychological function-
ing are limited by design issues.
The DAT1 gene may also influence the response to
medication. Thus, Loo et al. [111] reported that DAT1
alleles may mediate medication-related EEG changes in
ADHD, with children with ADHD and two copies of the
10-repeat allele showing increased and 9-repeat carriers
with ADHD showing decreased cortical activation and
arousal after a single 10-mg dose of methylphenidate.
Other dopaminergic genes
No clear evidence has been reported to support an asso-
ciation between ADHD and variations in the tyrosine
hydroxylase gene (TH), which catalyzes the conversion of
tyrosine to dopa. Ribases et al. [143] found the dopamine
decarboxylase gene (DDC)—whose enzyme is responsible
for catalyzing the conversion of dopa to dopamine and L-
5 hydroxytryptophan to serotonin—to be strongly asso-
ciated with both adult and childhood ADHD. Two further
studies support this finding: one analysis of the IMAGE
data [95] as well as a study on a Chinese Han sample also
found a nominally significant association [65]. There are,
however, also negative results from an earlier analysis
that included a subsample of patients from the IMAGE
sample [21].
Several studies have reported an association between
ADHD and a polymorphism (TaqI) of the dopamine beta
hydroxylase gene (DBH) that encodes for the enzyme that
catalyzes the conversion of dopamine to noradrenaline
(pooled odds ratio *1.3). However, there were differences
between studies with increased risk being associated with
the A2 allele in some studies, but with the A1 allele in
others [120, 180]. Bellgrove et al. [15, 16] reported an
association between the A2 allele of the TaqI DBH poly-
morphism and impaired temporal resolution and sustained
attention, with those homozygous for the A2 allele per-
forming worse than those without this genotype. Barkley
et al. [12] found the A2 allele to be associated with poor
performance on a card playing task in adulthood and, when
for individuals homozygous for A2, in adolescence. Kiel-
ing et al. [82] reported an association between a different
polymorphism of DBH—the -1021C[T polymorphism,
which may account for up to 50% reduction of the enzy-
matic activity—and measures of executive functioning in
64 drug-naive patients with ADHD. Cognitive performance
measured by a composite score was significantly different
between genotype groups, with the CC homozygous car-
riers having a poorer global executive performance. In
contrast, Hess et al. [75] detected no association between
the -1021C[T polymorphism and ADHD, but suggested
that the marker may be related to impulsive personality
traits in an adult ADHD sample. Finally, the re-analysis of
the IMAGE GWAS data revealed a nominally significant
association finding at the DBH locus and ADHD [95]; the
same finding was also described in a Chinese Han popu-
lation [65].
A recent meta-analysis of studies investigating the
association between the Val/Met polymorphism of the
catechol-o-methyltransferase (COMT) gene at codon 158
and ADHD concluded that the current evidence does not
support an association with the disorder [29]. This con-
clusion is supported by results from the IMAGE project on
Eur Child Adolesc Psychiatry (2010) 19:237–257 241
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this polymorphism [21]. Subsequent studies have reported
both association [47, 94, 95], no association [160] or a
more complicated mode of action. Halleland and co-
workers identified a haplotype including the Val158Met
polymorphism associated with adult ADHD [68]. A study
by Sengupta et al. [155] showed that the Val/Met poly-
morphism modulates task-oriented behaviour, but it does
not modulate the response of this behaviour to MPH
treatment. Moreover, a study by Retz et al. [140] reported
that a specific haplotype combination of COMT variants
and variants of the noradrenaline transporter gene (NET/
SLC6A2, see below) may be related to low ADHD scores.
Furthermore, a report by Thapar et al. [171] suggests that
the Val158Met variation in the COMT gene previously
associated with altered executive functioning is actually
associated with antisocial behaviour in ADHD, rather than
with ADHD itself. Caspi et al. [28] reported similar find-
ings showing that homozygous valine carriers at codon 158
of the COMT gene were more aggressive than those with
the other two genotypes. Consequently, other studies
focused on the relationship between COMT genotypes and
ADHD comorbid disorders, such as conduct disorder (CD)
and oppositional defiant disorder (ODD). Monuteaux et al.
[125] did not detect an association between SNPs in the
COMT gene and the risk for CD in an ADHD sample,
whereas Qian et al. [136] reported on an association of the
Val/Met variant with ADHD and comorbid ODD in a
Chinese sample.
A number of studies have reported on additional dopa-
minergic genes. A potential involvement of the MAOA
gene in ADHD was reported [35, 65, 149, 189] even
though these positive findings were inconsistent regarding
the risk alleles [120, 180]. Moreover, others failed to find
association [114, 136]. While it may still be possible that
variations in the MAOA gene are associated with persis-
tence of ADHD into adolescence [100] and play a role in
the variation in neuropsychological performance [149],
Thapar et al. [172] suggested that variation in MAOA is
associated with antisocial behaviour in ADHD, but not
with ADHD itself. Gender is a further factor that could
mask effects of the gene on ADHD, Rommelse et al. [149],
Das et al. [35] and recently Biederman et al. [19] reported
gender differences in the association between gene varia-
tion and ADHD traits and suggested that the MAOA gene
may explain some of the known gender differences in
ADHD. As a possible mode of action, Rommelse et al.
[149] described that an ATT haplotype of MAOA was
associated with poor motor control in boys whereas it was
associated with better visuo-spatial working memory in
girls. Besides the MAOA gene, there are also reports on
variants of the MAOB gene that were described to be
associated with adult ADHD in a Spanish sample [143] and
two additional studies [101, 143].
Noradrenergic system
While stimulant medications appear to act primarily by
regulating dopamine levels in the brain, noradrenergic and
serotonergic functions may also be affected by ADHD
medications [159]. In addition, adrenergic neurotransmitter
systems are hypothesized to influence attentional processes
and certain aspects of executive control [4]. The most
frequently investigated genes of the noradrenergic system
are those encoding the noradrenaline transporter (NET1/
SLC6A2) and the adrenergic alpha receptors 2A and 2C
(ADRA2A and ADRA2C). Additionally, there is some evi-
dence for a potential involvement of the genes for alpha
receptors-1A and 1B (encoded by ADRA1A and ADRA2B)
and beta receptor 1 and 2 (ADRB1 and ADRB2) in the
aetiology of ADHD [95].
An initial positive finding for the noradrenaline trans-
porter (NET1/SLC6A2) [34] was followed by several
studies that found no association [13, 30, 119]. Recently,
several additional variants of the noradrenaline transporter
have been associated to ADHD [20, 22, 65, 83, 84, 86, 95,
191, 192] and require further attention and more elaborate
analyses. One example of such an analysis was already
described above, suggesting that variations in the nor-
adrenaline transporter may show effects in the presence of
specific variants in the COMT gene (and vice versa), only
[140]. Additionally, two studies also suggested gender-
specific effects: Biederman et al. [19] found variants in
NET1/SLC6A2 to be associated more strongly with ADHD
in females, whereas Anney et al. [2] reported about
paternal over transmission of risk alleles to affected
individuals.
Regarding other candidate genes of the noradrenergic
system, there is growing evidence for involvement of
genetic variants of the adrenergic receptor alpha-2A gene
(ADRA2A) in ADHD [2, 30, 39, 145, 152, 184]. It may be
that these variants are more relevant for inattentive than
hyperactive/impulsive symptoms [145, 152]. Also it has
been suggested that there is a relationship between
ADRA2A polymorphisms and neuropsychological func-
tioning that may moderate but not mediate the association
to ADHD [181].
Investigating another adrenergic receptor gene, Cho
et al. [31] reported associations between variants of the
alpha-2C adrenergic receptor gene (ADRA2C) and ADHD
in their sample of Korean subjects. They found that
homozygous carriers of the C allele of the Dral polymor-
phism in ADRA2C showed a trend towards increased
response time variability while individuals homozygous for
the G allele at the Mspl polymorphism had a trend towards
decreased response time variability. Guan et al. [65]
reported suggestive significance for an association of
ADRA2C variants with ADHD combined type.
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Finally, the alpha-1A adrenergic receptor gene
(ADRA1A) and the beta-2 adrenergic receptor gene
(ADRB2) were two of the genes with nominal significance
in the study of Brookes et al. [21] that were also identified
by Lasky-Su et al. [95]. Very recently, Elia et al. [47] also
described a potential association between ADRA1A and
ADHD.
Serotonergic system
Serotonin dysregulation has been related to impulsive
behaviour in children [69], and thus has been hypothesized
to play a causal role in ADHD [129]. ‘‘Knockout’’ gene
studies in mice, in which the behavioural effects of the
deactivation of specific genes are examined, have further
demonstrated the potential relevance of serotonergic genes
[60]. The main candidate genes studied within the seroto-
nergic system are those coding for the serotonin transporter
(5-HTT/SLC6A4), the 1B and 2A serotonin receptors
(HTR1B) and (HTR2A) and the dopamine decarboxylase
(DDC) and tryptophan hydroxylase (TPH2) genes. Several
other serotonin receptor genes have also been studied much
less extensively.
A meta-analysis has supported an association between
ADHD and a 44-base-pair insertion/deletion (5-HTTLPR)
in the promoter region of the serotonin transporter gene (5-
HTT/SLC6A4); this insertion/deletion causes long or short
alleles with the long variant coding a functionally more
active transporter which may contribute to the ADHD
association (pooled odds ratio *1.3) [53]. However,
although there have been further replications since this
meta-analysis [89, 104, 139] several studies have failed to
replicate this finding [21, 64, 120, 187, 188] while still
others have found the other allele to be associated [1, 104].
Moreover, there have also been reports that the association
of 5-HTTLPR may only be present when paired with an
intron-2 (STin2) polymorphism [11] and that the intron-2
(STin2) polymorphism itself may be the variant more rel-
evant for ADHD.
There are also contradictory findings for the potential
association of the serotonin receptors with ADHD. A meta-
analysis supported an association between the HTR1B gene
and ADHD (pooled odds ratio *1.44; [53]), and although
there are subsequent additional replications for HTR1B [70,
137], there are again also negative findings [21, 77]. Sim-
ilarly, several groups have reported positive findings for
HTR2A [67, 143], whilst others have failed to find an
association [40, 146]. An analysis of the IMAGE study
reported an association with the previously unstudied
HTR1E gene but did not find an association to HTR2C or
HTR3B [95]. Isolated findings in Chinese Han subjects and
others have been reported for several other serotonin
receptor genes including those coding for HTR1D [108,
109], HTR2C [106, 190] and HTR4 [102] but not others
HTR5A and HTR6 [103]. Li et al. [99] also reported that
polymorphisms of the HTR2A and HTR2C genes are rela-
ted to functional remission in ADHD.
Li and colleagues have also reported on ADHD asso-
ciations for the tryptophan hydroxylase 2 gene (TPH2)
which mediates the transformation of tryptophan to 5-hy-
droxytryptophan [105, 107]. These findings have been
replicated in independent samples [21, 95, 157, 182].
Moreover, an analysis of the IMAGE data revealed nomi-
nal significance for an association between TPH2 variants
and overt aggressive impulsivity [130]. Baehne et al. [8]
reported that TPH2 gene variants modulate response con-
trol processes in adult ADHD patients and healthy indi-
viduals. Regarding tryptophan hydroxylase 1 (TPH1), no
ADHD association was found in the IMAGE sample [21].
Finally, Ribases et al. [143] reported that the DDC gene,
which mediates the transformation of 5-hydroxytryptophan
to serotonin, is associated to both adult and childhood
ADHD.
Other candidate genes
Additional candidate genes that have been studied include
genes related to the following non-exhaustive list of gene
products: Synaptosome-associated protein of 25,000 Da
(SNAP25), nicotinic acetylcholine receptor alpha 4
(CHRNA4), the glutamate (NMDA) receptor, brain derived
neurotrophic factor (BDNF), nerve growth factor (NGF)
and its receptor (NGFR), neurotrophins 3 and 4/5 (NTF3
and NTF4/5), ciliary neurotrophic factor (CNTF) and its
receptor (CNTFR), glial derived neurotrophic factor
(GDNF) and the receptors for neurotrophic tyrosine kinase,
type 1–3 (NTRK1, NTRK2 and NTRK3), low affinity nerve
growth factor receptor (LNGFR or p75 neurotrophin
receptor), solute carrier family member 9A9 (SLC9A9),
cannabinoid receptor 1 (CNR1/CB1) and nitric oxide syn-
thase 1 (NOS1) [21, 95].
For SNAP25, meta-analyses of studies indicated signif-
icance of association findings for ADHD [52], for SLC9A9
also cytogenetic findings point to a role in ADHD [38], and
for the functional Val66Met variant of BDNF, a very recent
meta-analysis of the IMpACT project data showed no
association with ADHD with or without comorbid mood
disorders, in a large clinical sample of clinical adult ADHD
cases (n = 1,445) and controls (n = 2,247) [151]. For the
other genes mentioned above the results of the association
analyses are either first reports based on samples of small
or moderate size or where there is more than one report
with contradictory findings. Obviously, contradictory
results can arise for many reasons, but inadequate power to
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detect associations with small effect sizes and inexplicit
analysis plans with multiple post hoc comparisons are the
most common and obvious problems. To address this issue,
carefully planned meta-analyses on studies with adequate
quality or primary studies of sufficient size are needed.
Genome-wide association studies in ADHD
Genome-wide association studies have been a very suc-
cessful tool for the recent identification of multiple risk
genes for multifactorial (complex) disorders [116]. They
combine the power to detect genetic variants of small
effect size, like the association studies, with the possibility
to perform hypothesis-free analyses of the entire genome.
However, large sample sizes are needed in order to detect
genetic risk factors with modest effects. So far, GWAS in
ADHD have been published for two different samples, a
subsample of the International Multicentre ADHD Genet-
ics (IMAGE) study on childhood ADHD and a sample of
adults with ADHD. These studies will be reviewed below.
For a more detailed review see also [56].
The various GWAS analyses of the IMAGE sample that
were published together in a special issue on ADHD
genetics in the Am. J. Med. Genet. Part B (2008), used
different approaches to identify risk genes. The IMAGE
GWAS sample comprised a sample of 958 case-parent
trio’s with most of the cases diagnosed with combined
subtype ADHD. The data were analysed using both quan-
titative [95] and categorical [127] phenotype definitions.
The quantitative analysis revealed two significant findings:
one for a genetic variant in the CDH13 gene associated
with total ADHD symptom count, the other for a genetic
variant in GFOD1, the gene coding for glucose-fructose
oxidoreductase domain containing protein 1, associated
with inattentive symptoms. Another interesting finding
from this study (though not statistically significant) inclu-
ded a variant in NOS1, which had previously been identi-
fied as a candidate gene for ADHD [138]. The categorical
analysis did not reveal any genes or variants of genome-
wide significance, but CDH13 was also among the top-
findings identified in this analysis, as was a variant in
CNR1/CB1, a gene found associated with ADHD in earlier
candidate gene based association studies [113, 133].
A whole genome gene-environment interaction study of
parental expressed emotion (maternal warmth and criti-
cism) looking at ADHD severity (and conduct problems)
was also conducted using the same dataset, although there
were again no genome-wide significant findings [162].
Additional GWAS in the IMAGE dataset so far included a
study of time of onset of hyperactive/impulsive and inat-
tentive symptoms [94] and one on conduct problems in
ADHD [2].
The GWAS of adult ADHD patients used a pooled
approach involving 343 adult ADHD patients and 304
controls [96]. The results of this study were compared to
those of a linkage analysis carried out earlier by the same
group [146] to prioritize the most interesting findings for
further analysis. Although no genome-wide significant
variants resulted from this study, the highest ranking
findings also include the CDH13 gene. This gene emerges
hitherto as one of the most consistent findings from the
ADHD GWAS. In addition, it is supported by other sour-
ces, e.g. being located on chromosome 16q24 within the
only significant linkage peak from a meta-analysis of seven
linkage studies in ADHD [196]. Since CDH13 also showed
association with different addiction-related phenotypes in
GWAS (review by Uhl et al. [175]), was among the top-
findings from a GWAS of the personality trait extraversion
[170], showed strong association with schizophrenia in a
genome-wide study [164], and may contain copy number
variants (CNV) related to autism [32], it seems to be a
generalist gene, predisposing to multiple brain phenotypes
[90]. CDH13 encodes cadherin 13, a protein expressed in
neurons regulating cell migration and cell–cell communi-
cation [56].
Although only very few significant findings emerged
from the individual ADHD GWAS, so far, and overlap
between studies is still very limited, there are a few sys-
tems that seem to be overrepresented in the top-ranks of the
different studies and a number of general themes seem to
be emerging from the data. The most striking one is the
possible involvement of genes related to cell adhesion and
cell migration in ADHD aetiology, such as genes from
cadherin, catenin and integrin families (Table 1), with
CDH13 as the top-finding.
A second system showing up in these studies is that of
potassium-related signalling (Table 2). This type of sig-
nalling is involved in regulating synaptic excitability and
neuronal plasticity [85]. An interesting finding from the
GWAS is that whilst signals relating to cell–cell commu-
nication genes related to glutamate, vasopressin and TAFA
mediated signalling are observed the classical catechol-
aminergic and serotonergic neurotransmission ADHD
candidate genes are absent from the high-ranking findings.
However, since the power of these studies is still rather
limited, the involvement of the genes for the classical
neurotransmission systems in ADHD aetiology is not
precluded.
Notably, nearly all of the genes listed in the top-ranks of
the published ADHD GWAS belong to the largest genes
within the human genome (Franke, unpublished observa-
tion), which may also point to insufficient power of the
studies to detect association with smaller genes. As indi-
cated above, some of the genes from candidate gene studies
do show up in the GWAS, most notably CNR1 and NOS1.
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Also more basic cell processes related to cell division, gene
transcription, cell polarity and extracellular matrix regula-
tion, as well as cytoskeletal remodeling could be involved
in ADHD [95, 96, 127]; see [56] for a review.
Whilst the current GWAS published for ADHD are far
from providing a full understanding of the processes con-
tributing to ADHD, they do provide us with new directions
and suggest avenues follow. Comparing the findings to
those from GWAS and linkage studies in other psychiatric
disorders suggests extensive overlap between disorders. If
this is due to overlap at the level of diagnostics or to
genetic overlap between disorders remains to be explored.
Future directions in ADHD genetics research
To date, the findings from genetic studies in ADHD have
been somewhat inconsistent and disappointing. Despite the
high heritability of the disorder, linkage studies have not
shown extensive overlaps, with only one significant finding
in the meta-analysis of studies [196]. Candidate gene based
association studies have similarly only explained a small
percentage of the genetic component of ADHD and the first
GWAS did not report many significant findings. Never-
theless, the latter approach is likely to redirect future
ADHD research given the apparent involvement of new
gene systems and processes, as summarized above.
Comparing GWAS in psychiatric disorders in general
with those in other multifactorial diseases one finds that
the performance of GWAS in psychiatric disorders has
been particularly poor, explaining less than 10% of the
observed variance for most of the disorders, so far [115].
The failure of the GWAS to identify the genes involved
in psychiatric disorders with high heritability may have a
number of causes: (1) multiple genetic factors may be
involved that may have very small individual effects and
might only be identified through studies with extremely
large sample sizes; (2) gene–gene (G 9 G) and gene-
environment (G 9 E) interactions may be making a
strong contribution to the observed heritability of psy-
chiatric disorders; (3) genetic factors other than the single
nucleotide polymorphisms (SNPs) investigated in most
studies may play important roles; thus, CNVs, i.e.,
structural variations in DNA, such as insertions, deletions
and duplications, which are frequently occurring but
widely varying in the population, might be involved in
ADHD aetiology; (4) the role of rare genetic variants with
large effect sizes in disease aetiology may be greater than
anticipated; (5) the currently available nosological sys-
tems used for the clinical diagnosis of psychiatric disor-
ders may be clinically valid but may not be strongly
related to the biological underpinnings of such disorders,
or may not be specific enough to pick up genes; and (6) itT
a
b
le
1
co
n
ti
n
u
ed
S
N
P
P
v
al
u
e
C
h
r
P
o
si
ti
o
n
(b
p
)
P
o
si
ti
o
n
G
en
e
fu
n
ct
io
n
a
A
d
d
it
io
n
al
re
m
ar
k
s
rs
8
7
4
4
2
6
3
.7
5
E
-
0
6
d
1
1
1
9
5
2
6
1
3
9
In
in
tr
o
n
o
f
N
A
V
2
E
n
co
d
es
n
eu
ro
n
n
av
ig
at
o
r
2
,
an
re
ti
n
o
ic
ac
id
-r
es
p
o
n
si
v
e
g
en
e
th
at
se
em
s
to
p
la
y
a
ro
le
in
n
eu
ro
n
al
d
ev
el
o
p
m
en
t.
It
is
h
ig
h
ly
ex
p
re
ss
ed
in
fe
ta
l
an
d
ad
u
lt
b
ra
in
.
L
ie
s
w
it
h
in
/c
lo
se
to
li
n
k
ag
e
re
g
io
n
fo
r
au
ti
sm
fr
o
m
p
ri
m
ar
y
st
u
d
ie
s
an
d
m
et
a-
an
al
y
si
s
[4
6
,
1
6
8
,
1
7
3
].
G
en
e
is
as
so
ci
at
ed
w
it
h
b
ip
o
la
r
d
is
o
rd
er
in
G
W
A
S
at
p
v
al
u
es
o
f
1
0
-
4
[1
5
8
]
A
ss
o
ci
at
ed
w
it
h
an
ea
rl
ie
r
o
n
se
t
o
f
A
D
H
D
sy
m
p
to
m
s
in
L
as
k
y
-S
u
et
al
.
[9
4
].
A
ls
o
as
so
ci
at
ed
w
it
h
A
D
H
D
at
p
=
1
0
-
4
in
G
W
A
S
o
f
N
ea
le
et
al
.
[1
2
7
]
a
W
h
er
e
n
o
t
in
d
ic
at
ed
o
th
er
w
is
e,
th
e
in
fo
rm
at
io
n
is
d
er
iv
ed
fr
o
m
th
e
U
C
S
C
B
ro
w
se
r,
N
C
B
I’
s
O
M
IM
,
G
en
e
an
d
U
n
ig
en
e
d
at
ab
as
es
,
an
d
th
e
S
u
ll
iv
an
L
ab
E
v
id
en
ce
P
ro
je
ct
w
eb
si
te
(l
o
ca
ti
o
n
o
f
S
N
P
ex
p
an
d
ed
b
y
±
5
m
b
fo
r
g
en
o
m
e-
w
id
e
li
n
k
ag
e
sc
an
s,
±
5
k
b
fo
r
G
W
A
S
,
m
ic
ro
ar
ra
y
an
d
C
N
V
st
u
d
ie
s,
an
d
±
5
0
k
b
fo
r
si
g
n
p
o
st
s)
b
T
h
es
e
fi
n
d
in
g
s
w
er
e
d
er
iv
ed
u
si
n
g
th
e
P
B
A
T
sc
re
en
in
g
p
ro
ce
d
u
re
p
ri
o
r
to
as
so
ci
at
io
n
te
st
in
g
c
T
D
T
an
al
y
si
s
d
F
B
A
T
an
al
y
si
s
*
*
A
N
O
V
A
p
v
al
u
e
fo
r
ra
n
k
in
g
Eur Child Adolesc Psychiatry (2010) 19:237–257 247
123
T
a
b
le
2
G
en
es
en
co
d
in
g
p
ro
te
in
s
re
la
te
d
to
p
o
ta
ss
iu
m
-m
ed
ia
te
d
si
g
n
al
li
n
g
(G
W
A
S
fi
n
d
in
g
s)
S
N
P
P
v
al
u
e
C
h
r
P
o
si
ti
o
n
(b
p
)
P
o
si
ti
o
n
G
en
e
fu
n
ct
io
n
a
A
d
d
it
io
n
al
re
m
ar
k
s
rs
8
7
6
4
7
7
2
.6
9
E
-
0
5
b
4
2
0
7
6
6
0
2
6
In
tr
o
n
o
f
K
C
N
IP
4
E
n
co
d
es
K
v
ch
an
n
el
in
te
ra
ct
in
g
p
ro
te
in
4
is
o
fo
rm
3
,
a
m
em
b
er
o
f
th
e
fa
m
il
y
o
f
v
o
lt
ag
e-
g
at
ed
p
o
ta
ss
iu
m
(K
v
)
ch
an
n
el
-i
n
te
ra
ct
in
g
p
ro
te
in
s
(K
C
N
IP
s)
,
an
d
m
ay
re
g
u
la
te
A
-t
y
p
e
cu
rr
en
ts
,
an
d
h
en
ce
n
eu
ro
n
al
ex
ci
ta
b
il
it
y
,
in
re
sp
o
n
se
to
ch
an
g
es
in
in
tr
ac
el
lu
la
r
ca
lc
iu
m
.
T
h
e
K
C
N
IP
4
p
ro
te
in
al
so
in
te
ra
ct
s
w
it
h
p
re
se
n
il
in
.
G
en
e
is
al
so
fo
u
n
d
am
o
n
g
to
p
-fi
n
d
in
g
s
fr
o
m
G
W
A
S
in
sc
h
iz
o
p
h
re
n
ia
[1
6
4
]
an
d
sh
o
w
s
p
v
al
u
es
o
f
1
0
-
5
in
G
W
A
S
in
b
ip
o
la
r
d
is
o
rd
er
[1
5
8
]
N
ea
le
et
al
.
[1
2
7
].
A
ls
o
sh
o
w
s
n
o
m
in
al
as
so
ci
at
io
n
(p
\
0
.0
5
)
in
q
u
an
ti
ta
ti
v
e
G
W
A
S
b
y
L
as
k
y
-S
u
et
al
.
[9
5
]
rs
1
5
4
1
6
6
5
5
.6
0
E
-
0
5
b
5
1
7
0
0
7
5
4
9
5
In
tr
o
n
o
f
K
C
N
IP
1
E
n
co
d
es
K
v
ch
an
n
el
in
te
ra
ct
in
g
p
ro
te
in
1
is
o
fo
rm
2
,
a
m
em
b
er
o
f
th
e
fa
m
il
y
o
f
v
o
lt
ag
e-
g
at
ed
p
o
ta
ss
iu
m
(K
v
)
ch
an
n
el
-i
n
te
ra
ct
in
g
p
ro
te
in
s
(K
C
N
IP
s)
,
an
d
m
ay
re
g
u
la
te
A
-t
y
p
e
cu
rr
en
ts
,
an
d
h
en
ce
n
eu
ro
n
al
ex
ci
ta
b
il
it
y
,
in
re
sp
o
n
se
to
ch
an
g
es
in
in
tr
ac
el
lu
la
r
ca
lc
iu
m
.
L
ie
s
cl
o
se
to
li
n
k
ag
e
re
g
io
n
o
b
se
rv
ed
in
se
v
er
al
p
ri
m
ar
y
st
u
d
ie
s
as
w
el
l
as
a
m
et
a-
an
al
y
si
s
[9
7
].
G
en
e
is
al
so
fo
u
n
d
in
G
W
A
S
in
sc
h
iz
o
p
h
re
n
ia
w
it
h
p
v
al
u
es
o
f
1
0
-
4
[1
6
4
]
N
ea
le
et
al
.
[1
2
7
].
A
ls
o
sh
o
w
s
n
o
m
in
al
as
so
ci
at
io
n
(p
\
0
.0
5
)
in
q
u
an
ti
ta
ti
v
e
G
W
A
S
b
y
L
as
k
y
-S
u
et
al
.
[9
5
]
rs
2
7
2
0
0
0
9
.1
0
E
-
0
6
c
2
1
1
6
3
7
2
2
6
5
W
it
h
in
5
0
k
b
d
o
w
n
st
re
am
o
f
D
P
P
1
0
E
n
co
d
es
d
ip
ep
ty
l
p
ep
ti
d
as
e
1
0
,
w
h
ic
h
d
o
es
n
o
t
p
o
ss
es
s
d
ip
ep
ti
d
y
l
p
ep
ti
d
as
e
ac
ti
v
it
y
b
u
t
b
in
d
s
to
sp
ec
ifi
c
v
o
lt
ag
e-
g
at
ed
p
o
ta
ss
iu
m
ch
an
n
el
s
an
d
al
te
rs
th
ei
r
ex
p
re
ss
io
n
an
d
b
io
p
h
y
si
ca
l
p
ro
p
er
ti
es
.
T
h
e
ex
p
re
ss
io
n
o
f
th
e
g
en
e
is
h
ig
h
es
t
in
b
ra
in
.
T
h
e
fi
n
d
in
g
li
es
w
it
h
in
a
li
n
k
ag
e
re
g
io
n
fo
r
sc
h
iz
o
p
h
re
n
ia
o
b
se
rv
ed
in
m
et
a-
an
al
y
si
s
an
d
se
v
er
al
p
ri
m
ar
y
st
u
d
ie
s
[9
7
].
In
ad
d
it
io
n
,
th
e
g
en
e
sh
o
w
ed
as
so
ci
at
io
n
in
G
W
A
S
o
f
sc
h
iz
o
p
h
re
n
ia
[1
6
4
]
an
d
b
ip
o
la
r
d
is
o
rd
er
[1
8
5
]
at
p
=
1
0
-
5
,
an
d
co
n
ta
in
s
C
N
V
s
p
o
te
n
ti
al
ly
li
n
k
ed
to
au
ti
sm
[1
1
8
]
A
ss
o
ci
at
ed
w
it
h
to
ta
l
sy
m
p
to
m
co
u
n
t,
L
as
k
y
-S
u
et
al
.
[9
5
].
S
it
e
k
n
o
w
n
fo
r
C
N
V
s
rs
6
7
9
1
6
4
4
8
.3
2
E
-
0
6
c
3
6
0
7
4
6
1
4
8
In
in
tr
o
n
o
f
F
H
IT
E
n
co
d
es
a
d
ia
d
en
o
si
n
e
5
0 ,5
000
-P
1
,P
3
-t
ri
p
h
o
sp
h
at
e
h
y
d
ro
la
se
in
v
o
lv
ed
in
p
u
ri
n
e
m
et
ab
o
li
sm
.
F
H
IT
h
as
a
m
aj
o
r
ro
le
in
re
g
u
la
ti
n
g
b
et
a-
ca
te
n
in
-m
ed
ia
te
d
g
en
e
tr
an
sc
ri
p
ti
o
n
.
E
x
p
re
ss
io
n
in
m
an
y
ti
ss
u
es
in
cl
u
d
in
g
b
ra
in
.
G
en
e
is
al
so
fo
u
n
d
am
o
n
g
to
p
-fi
n
d
in
g
s
fr
o
m
G
W
A
S
in
sc
h
iz
o
p
h
re
n
ia
[1
6
4
]
an
d
is
af
fe
ct
ed
b
y
C
N
V
s
in
au
ti
sm
[1
1
8
,
1
5
4
]
A
ss
o
ci
at
ed
w
it
h
to
ta
l
sy
m
p
to
m
co
u
n
t,
L
as
k
y
-S
u
et
al
.
[9
5
]
rs
3
8
9
3
2
1
5
2
.5
6
E
-
0
5
*
*
1
1
1
7
7
2
1
4
0
6
In
in
tr
o
n
o
f
K
C
N
C
1
E
n
co
d
es
p
o
ta
ss
iu
m
v
o
lt
ag
e-
g
at
ed
ch
an
n
el
S
h
aw
-r
el
at
ed
su
b
fa
m
il
y
m
em
b
er
1
,
a
p
ro
te
in
b
el
o
n
g
in
g
to
th
e
d
el
ay
ed
re
ct
ifi
er
cl
as
s
o
f
ch
an
n
el
p
ro
te
in
s
an
d
an
in
te
g
ra
l
m
em
b
ra
n
e
p
ro
te
in
th
at
m
ed
ia
te
s
th
e
v
o
lt
ag
e-
d
ep
en
d
en
t
p
o
ta
ss
iu
m
io
n
p
er
m
ea
b
il
it
y
o
f
ex
ci
ta
b
le
m
em
b
ra
n
es
.
T
h
e
fi
n
d
in
g
is
p
re
se
n
t
cl
o
se
to
/w
it
h
in
re
g
io
n
s
o
f
(s
u
g
g
es
ti
v
e)
li
n
k
ag
e
to
au
ti
sm
fr
o
m
m
et
a-
an
al
y
si
s
[1
7
3
]
an
d
p
ri
m
ar
y
st
u
d
ie
s
[4
6
,
1
6
7
]
L
es
ch
et
al
.
[9
6
]
a
W
h
er
e
n
o
t
in
d
ic
at
ed
o
th
er
w
is
e,
th
e
in
fo
rm
at
io
n
is
d
er
iv
ed
fr
o
m
th
e
U
C
S
C
B
ro
w
se
r,
N
C
B
I’
s
O
M
IM
,
G
en
e
an
d
U
n
ig
en
e
d
at
ab
as
es
,
an
d
th
e
S
u
ll
iv
an
L
ab
E
v
id
en
ce
P
ro
je
ct
w
eb
si
te
(l
o
ca
ti
o
n
o
f
S
N
P
ex
p
an
d
ed
b
y
±
5
m
b
fo
r
g
en
o
m
e-
w
id
e
li
n
k
ag
e
sc
an
s,
±
5
k
b
fo
r
G
W
A
S
,
m
ic
ro
ar
ra
y
an
d
C
N
V
st
u
d
ie
s,
an
d
±
5
0
k
b
fo
r
si
g
n
p
o
st
s)
b
T
D
T
an
al
y
si
s
c
F
B
A
T
an
al
y
si
s
*
*
A
N
O
V
A
p
v
al
u
e
fo
r
ra
n
k
in
g
248 Eur Child Adolesc Psychiatry (2010) 19:237–257
123
must be kept in mind, that the samples studied differ in
age (persistent vs. non-persistent ADHD), method of
recruitment and ascertainment, ethnicity, gender and
comorbidity and that each of these factors might have an
impact. These issues need to be dealt with, before we can
fully understand the genetic architecture of ADHD. The
issue of sample size is currently tackled by establishing
large international collaborations, such as the ADHD
Molecular Genetics Network [49] and the Psychiatric
GWAS Consortium [134], and large (meta-analytic)
studies of GWAS in ADHD can be expected within the
next year. The G 9 G and G 9 E effects are not yet
taken into account in most current studies, but some
potentially important G 9 G and G 9 E interactions have
been demonstrated. It is likely that new statistical
approaches will need to be developed, before we can
sufficiently handle these effects with confidence. Until
now, most studies have focussed on SNPs only, however,
this type of polymorphism is not informative for all
genetic factors present in the human genome, and we
might need to use other techniques, such as next gener-
ation sequencing [153] to get more information on these
other genetic factors. This approach may also solve the
problem with rare variants. Point (5), the potential limi-
tations through the use of the current diagnostic system
for genetic studies, can potentially be addressed by using
more refined phenotypes. Refinement of the ADHD phe-
notype may be possible by concentrating on the most
heritable subtypes of ADHD. This has already been
implemented in the IMAGE study, which concentrated on
combined subtype ADHD [91]. Recently, the IMpACT
project was set up by research groups from The Nether-
lands, Germany, Spain, Norway, the UK and the US to
perform and promote genetic research in the persistent,
adult form of ADHD [57]. Although the heritability of
this form of the disorder has not formally been estab-
lished, it seems that it may be higher than that of the
childhood disorder [48]. To date, IMpACT coordinates
the largest clinical sample of adult ADHD, with more
than 2,700 cases and 3,500 controls. A more radical
adaptation in phenotypes for genetic studies in ADHD is
the use of endophenotypes. Endophenotypes, or interme-
diate phenotypes, are thought to represent heritable phe-
notypic constructs that are more directly related to genes
than clinical symptoms or disease categories [63, 169,
183]. The success of an endophenotype strategy requires
either a higher heritability of the endophenotype as
compared to the disease phenotype (which is not gener-
ally observed, [167]) or a reduced complexity of the
genetic architecture of the endophenotype due to the
involvement of fewer genes. ADHD endophenotypes have
been identified at different levels, based on neuropsy-
chological performance [41, 147] and on neuroimaging
[43] i.e. brain activity and structure. Such studies seem to
work well, the first examples of linkage studies show
significant findings in samples of relatively limited size
(e.g. [42, 150]) and so do (candidate gene based) asso-
ciation findings (e.g. references to Durston et al. [45]).
Especially the latter seem to produce more highly pow-
ered studies due to larger effect sizes of individual genetic
variants [121, 126]. The penetrance of genetic variants
may be especially high for functional neuroimaging
[121]). However, it needs to be taken into account that
initial studies of genetic associations frequently tend to
over-estimate true effect sizes [174]; thus, we need to be
cautious about interpretation of the initial studies of
endophenotypes in relatively small sample sizes.
Endophenotype approaches come at the cost of reduced
specificity for ADHD, so not all genes explaining variance
of an endophenotype will also increase ADHD risk in the
end; however, it is not yet clear whether factors such as
course or treatment response are more closely related to
ADHD per se or to a particular endophenotype.
Furthermore, endophenotype studies will also help to
characterize the neural systems affected by risk gene
variants and to elucidate quantitative, mechanistic aspects
of brain function implicated in ADHD, and thus improve
our understanding of the functional role of genes in ADHD
and the specific pathways from gene to behaviour.
In conclusion, genetic studies have started to unravel the
molecular architecture of ADHD, and several new exciting
directions have recently been suggested. Future success in
identifying more ADHD genes will critically depend on
collaboration between researchers and an improvement of
approaches at the level of the phenotype definition, the
molecular genetic techniques, as well as statistical analysis
methods. Even if the ADHD risk genes have such small
effect sizes in the population, their identification may still
be highly relevant clinically, because low frequency gene
variants may actually explain most of the heritability in
individual patients and because a subsequent understanding
of their functions and the pathways between each gene and
behaviour may finally translate into an improvement of
diagnostic processes and treatment strategies as well as a
development of prediction and prevention programs with
substantial impact [132].
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